<DOC>
	<DOC>NCT00725478</DOC>
	<brief_summary>The aim of the non-interventional Post Marketing Study is to investigate the use of the non-ergot dopamine agonist piribedil (trade name: CLARIUM) in mono- and combination therapy in patients with Morbus Parkinson. Tolerability and course of the disease or change of parkinsonian symptoms during stabilisation on, or change over from other dopamine agonists will be documented under routine conditions. Piribedil should be prescribed according to its marketing authorisation by the responsible neurologist.</brief_summary>
	<brief_title>SEDPARK1: Safety and Efficacy Study With the Non-ergot Dopamine-agonist Piribedil in Parkinson's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Dopamine</mesh_term>
	<mesh_term>Dopamine Agents</mesh_term>
	<mesh_term>Piribedil</mesh_term>
	<mesh_term>Dopamine Agonists</mesh_term>
	<criteria>Male and female patients 18 years and older. Indication: Morbus Parkinson. Treatment with piribedil for the first time. Monotherapy with piribedil. Combination therapy with LDopa (from the beginning or secondary) and/or in combination with other antiparkinsonian drugs.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>Piribedil (trade name: CLARIUM)</keyword>
	<keyword>non-ergot dopamine agonist</keyword>
	<keyword>Morbus Parkinson</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Post Marketing Surveillance</keyword>
</DOC>